title: Comparison of cost-effectiveness of regorafenib and trifluridine/tipiracil combination tablet for treating advanced and recurrent colorectal cancer.
abstract: Regorafenib and trifluridine/tipiracil combination tablet regimens are standard third-line or later treatments for advanced and recurrent colorectal cancer with no significant difference in efficacy. The present study aimed to compare the cost-effectiveness of using regorafenib vs. the trifluridine/tipiracil combination tablet. The expected cost was calculated based on data from patients with advanced and recurrent colorectal cancer who were treated with regorafenib or trifluridine/tipiracil combination tablet. The median survival time (MST) from the CORRECT and the RECOURSE study was used to evaluate the therapeutic efficacy of the regimens. The cost-effectiveness ratio was calculated from the expected cost and MST for the two regimens. The expected cost per patient for the regorafenib and the trifluridine/tipiracil combination tablet regimen was ¥705,330.3 and ¥371,198.7, respectively, and the cost-effectiveness ratio was ¥110,207.9/MST and ¥52,281.5/MST, respectively. In conclusion, the findings of the present study demonstrated that the trifluridine/tipiracil combination tablet regimen is more cost-effective compared with the regorafenib regimen.
authors.affiliation: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan.
authors.forename: Michio
authors.initials: M
authors.lastname: Kimura
authors.affiliation: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan.
authors.forename: Eiseki
authors.initials: E
authors.lastname: Usami
authors.affiliation: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan.
authors.forename: Mina
authors.initials: M
authors.lastname: Iwai
authors.affiliation: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan.
authors.forename: Makiko
authors.initials: M
authors.lastname: Go
authors.affiliation: Laboratory of Clinical Pharmacy, Gifu Pharmaceutical University, Gifu-shi, Gifu 501-1196, Japan.
authors.forename: Hitomi
authors.initials: H
authors.lastname: Teramachi
authors.affiliation: Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu 503-8502, Japan.
authors.forename: Tomoaki
authors.initials: T
authors.lastname: Yoshimura
keywords: advanced and recurrent colorectal cancer; adverse event; cost-effectiveness; regorafenib; trifluridine/tipiracil combination tablet